- Resource
- BR1DGE
- Early Detection
- Staging
- Video
Islet Autoantibodies as Biomarkers of Progression to Clinical T1D
Prof Bonifacio discusses the predictive value and utility of islet autoantibodies as biomarkers of the risk and rate of progression to clinical T1D
Learning Objectives
- Understand the value of islet autoantibodies in detecting early-stage T1D and predicting onset of clinical disease
- Recognize how specific characteristics of islet autoantibodies, including number, type, titer, affinity, and age of onset, provide crucial insights into disease progression rate
Summary
At IDS, Prof. Bonifacio discussed the predictive value and utility of islet autoantibodies as biomarkers of the risk and rate of progression to clinical T1D.
Islet autoantibodies are powerful biomarkers of T1D risk, with the presence of two or more conferring a lifetime risk approaching 100%. In addition to their presence, a range of other autoantibody-related parameters provide further valuable information. These include autoantibody number, titer, type, and affinity, and the timing of their appearance. IA-2A antibodies are the strongest predictors of rapid progression, particularly in early-onset, multiple-antibody phenotypes. Conversely, transient single antibodies carry the lowest risk. Taken together, these antibody characteristics offer nuanced information that can help determine T1D risk and progression rate.
MAT-GLB-2600300 - 1.0 - 06/2026
Early T1D Screening Recommendations
Expert insights on recommendations for T1D screening, including proposed age ranges and opportunities for integration into existing public health touchpoints.
Supporting islet-autoantibody-positive individuals and their families
Appropriate strategies can help support people with early-stage T1D and their families and address anxiety during early T1D monitoring, ensuring optimal engagement and care.